In conclusion, they emphasized that preclinical trials using a fully humanized anti-METCAM antibody against melanoma growth and metastasis and using a mouse anti-METCAM monoclonal antibody against angiogenesis and tumor growth of hepatocarcinoma, leiomyosarcoma, and pancreatic cancer have been successfully demonstrated. Here, MCAM is linked to neoplasm.